Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
J Stroke Cerebrovasc Dis ; 31(7): 106511, 2022 Jul.
Article in English | MEDLINE | ID: mdl-35483241

ABSTRACT

OBJECTIVES: Ischemic stroke is a leading cause of death and disability worldwide. For patients with large vessel occlusion stroke, endovascular treatment is now the most effective treatment. We aimed to assess the outcome of patients undergoing endovascular treatment for large vessel occlusion stroke in a real-world setting, comparing our results with data from randomized clinical trials, and recognizing the factors associated with prognosis. MATERIALS AND METHODS: We retrospectively collected data on endovascular procedures performed in one comprehensive stroke center in consecutive patients presenting with large vessel occlusion stroke from January 2017 to January 2020. Data on baseline clinical, imaging, and treatment-related characteristics were recorded. Selection of patients and treatment approach was not standardized but followed current guidelines for ischemic stroke. Functional outcome was evaluated 3 months after endovascular treatment. Clinical, imaging and treatment-related variables associated to outcome were evaluated with univariate and multivariable analyses. RESULTS: Four hundred twelve patients were included in our study. Three-month functional independence was achieved in 50.5% of patients (50.3% in the anterior stroke and 52.1% in the posterior stroke subgroup). Successful arterial reperfusion was observed in 84.3% of patients. Age (odds ratio [OR] 0.41, 95% confidence interval [CI] 0.20-0.87, p = 0.020]), severe stroke at onset (OR 0.40, 95%CI 0.19-0.83), procedure related complications (OR 0.45, 95%CI 0.20-0.99), and good collateral circulation (OR 2.69, 95%CI 1.17-6.16) were associated with 3-month functional independence in multivariable model. CONCLUSIONS: Our real-world outcome results are in line with data from large randomized clinical trials on endovascular treatment for large vessel occlusion stroke.


Subject(s)
Endovascular Procedures , Ischemic Stroke , Endovascular Procedures/adverse effects , Humans , Ischemic Stroke/surgery , Randomized Controlled Trials as Topic , Retrospective Studies , Treatment Outcome
2.
J Pers Med ; 12(3)2022 Mar 15.
Article in English | MEDLINE | ID: mdl-35330468

ABSTRACT

In the last twelve years the clinical management of patients with atrial fibrillation has been revolutionised by the introduction of direct oral anticoagulants. Despite the large amount of evidence produced, some populations remain relatively poorly explored regarding the effectiveness and safety of direct oral anticoagulants, such as the oldest and/or frailest individuals. Frailty is clinical syndrome characterized by a reduction of functions and physiological reserves which results in individuals having higher vulnerability. While current evidence underlines a relationship between atrial fibrillation and frailty, particularly in determining a higher risk of adverse outcomes, data regarding effectiveness and safety of direct oral anticoagulants in frailty atrial fibrillation patients are still lacking, leaving uncertainty about how to guide prescription in this specific subgroup. On these premises, this multidisciplinary consensus document explains why it would be useful to integrate the clinical evaluation performed through comprehensive geriatric assessment to gather further elements to guide prescription of direct oral anticoagulants in such a high-risk group of patients.

3.
J Neurol ; 265(12): 2934-2943, 2018 Dec.
Article in English | MEDLINE | ID: mdl-30311053

ABSTRACT

BACKGROUND: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most common familial cerebral small vessel disease, caused by NOTCH3 gene mutations. The aim of our study was to identify clinical and neuroradiological features which would be useful in identifying which patients presenting with lacunar stroke and TIA are likely to have CADASIL. METHODS: Patients with lacunar stroke or TIA were included in the present study. For each patient, demographic and clinical data were collected. MRI images were centrally analysed for the presence of lacunar infarcts, microbleeds, temporal lobe involvement, global atrophy and white matter hyperintensities. RESULTS: 128 patients (mean age 56.3 ± 12.4 years) were included. A NOTCH3 mutation was found in 12.5% of them. A family history of stroke, the presence of dementia and external capsule lesions on MRI were the only features significantly associated with the diagnosis of CADASIL. Although thalamic, temporal pole gliosis and severe white matter hyperintensities were less specific for CADASIL diagnosis, the combination of a number of these factors together with familial history for stroke result in a higher positive predictive value and specificity. CONCLUSIONS: A careful familial history collection and neuroradiological assessment can identify patients in whom NOTCH3 genetic testing has a higher yield.


Subject(s)
Brain/diagnostic imaging , CADASIL/diagnosis , Neuroimaging , Receptor, Notch3/genetics , Adult , Aged , Atrophy , CADASIL/genetics , CADASIL/physiopathology , Cerebral Hemorrhage/diagnosis , Cerebral Hemorrhage/genetics , Cerebral Hemorrhage/physiopathology , Female , Humans , Ischemic Attack, Transient/diagnosis , Ischemic Attack, Transient/genetics , Ischemic Attack, Transient/physiopathology , Magnetic Resonance Imaging , Male , Middle Aged , Prospective Studies , Stroke, Lacunar/diagnosis , Stroke, Lacunar/genetics , Stroke, Lacunar/physiopathology , White Matter/diagnostic imaging
4.
Intervirology ; 58(5): 278-82, 2015.
Article in English | MEDLINE | ID: mdl-26595687

ABSTRACT

Multiple sclerosis (MS) is an autoimmune, demyelinating disorder of unknown etiology, in which viruses have been suggested as etiological/triggering agents. The attention to the association between viruses and MS has been rekindled by the development of progressive multifocal leukoencephalopathy in natalizumab-treated MS patients. Here we report the case of a woman with JC virus (JCV) replication in the cerebrospinal fluid, blood and urine collected at the first symptoms of MS and during several follow-up visits. This observation shows that JCV can be associated with MS without a relation with natalizumab treatment, although the triggering role of JCV in some cases of MS will require further studies.


Subject(s)
JC Virus/isolation & purification , Multiple Sclerosis/etiology , Polyomavirus Infections/complications , Tumor Virus Infections/complications , Blood/virology , Cerebrospinal Fluid/virology , Female , Humans , Polyomavirus Infections/virology , Tumor Virus Infections/virology , Urine/virology
SELECTION OF CITATIONS
SEARCH DETAIL
...